Please Explain the Problem About the Following Article, Please!?
Question by Jason K: please explain the problem about the following article, please!?
A diagnosis of prostate cancer is scary enough. But just as scary is that nobody can tell a man the best way to treat it.
This month, the Agency for Healthcare Research and Quality issued a sweeping review of prostate cancer treatments, including surgical removal, radiation, hormone therapy and so-called watchful waiting, which involves careful monitoring but no active treatment until the cancer shows signs of growing.
Because none of these treatments emerged as superior, the agency came to the troubling conclusion that it could not recommend one over the others.
“Having been involved in this area for a long time, it was not shocking, but it is disappointing,” said Dr. Timothy J. Wilt, lead researcher on the report, from the Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research. “Information is really lacking to determine whether over all one treatment is more effective and preferred.”
Prostate cancer is the single most common cancer in the United States and the second most lethal among men after lung cancer. In 2008, the American Cancer Society estimates, 186,320 men will learn that they have it and 28,660 will die from it. The estimates for breast cancer are 182,460 and 40,480.
Prostate cancer is often diagnosed with a blood test that looks for prostate-specific antigen, P.S.A. There is widespread consensus that the test casts too wide a net, resulting in overdiagnosis and overtreatment. And the treatment can be devastating, leaving men impotent, incontinent or both.
The reasons behind the lack of data on prostate cancer are complex. A lack of financing and advocacy have roles. But so does the fact that prostate tumors grow slowly and can take 10 or more years to turn deadly. Not only does that make the disease particularly expensive and time consuming to study, but it is also a built-in disincentive for the drug industry, which typically has patent protection from 7 to 20 years.
A bigger obstacle to finding answers may be the patients, who have long been reluctant to participate in clinical trials, and their doctors, who tend to scorn such trials because they are already convinced that their chosen treatment is the best option.
One major clinical trial called Spirit, for Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial, would have compared surgical removal with brachytherapy, which involves implanting radioactive seeds. Just 56 of the 1,980 needed patients enrolled, and the trial was called off in 2004.
“Men don’t go into the clinical trials,” said Dr. Daniel P. Petrylak, associate professor of medicine and director of the genitourinary oncology program at the Columbia University Medical Center. “That’s the whole problem. Patients ask me all the time, ‘What is the best treatment?’ And I can’t give them an evidence-based approach for that, because we don’t have the data.”
Prostate doctors and patient advocates often compare their cause with that of the other leading sex-specific cancer: one of the largest prostate cancer support groups is called Us Too, a play on the Y-ME National Breast Cancer Organization. The dismal state of prostate cancer research and advocacy pales in comparison to the campaign against breast cancer.
“We’re at least a decade behind where breast cancer awareness is,” Thomas Kirk, president of Us Too, said. “We need to catch up. The lessons learned by breast cancer are the ones we’re trying to apply to prostate cancer.”
Prostate cancer groups have tried to replicate the success of the pink ribbon campaign with their own blue ribbon, but it has yet to gain widespread acceptance. A group advocating the development of imaging technology for prostate screening created a mascot, Prosty the Spokesgland, complete with a theme song, to the tune of “Frosty the Snowman.” Not surprisingly, it has not caught on, either.
Government spending for prostate cancer lags, too. In 2007, the National Cancer Institute spent an estimated $ 551.1 million on breast cancer research and $ 305.6 million on prostate cancer. For 2008, the Defense Department, which has a history of supporting health research, has allocated $ 138 million for breast cancer and $ 80 million for prostate cancer.
Prostate cancer researchers say the real problem is not so much financing as enlisting doctors and patients on board for clinical trials.
By 2010, men should have some answers from Pivot, the Prostate Cancer Intervention Versus Observation Trial, which is comparing surgical removal with watchful waiting. Results of studies looking at P.S.A. screening as well as the preventive benefits of the supplements vitamin E and selenium are also expected in a few years
Best answer:
Answer by Thomas K
This article puzzles me. I was diagnosed with prostate cancer last fall, and I had all kinds of options.
As for the PSA test casting a wide net, the doctors all admit that a high PSA test doesn’t represent cancer, and to the best of my knowledge, no one undergoes cancer treatment based on one PSA test; the tip-off for a closer look is called PSA acceleration, or a rapid change in the PSA.
My PSA jumped from 1.5 to a 2.3 in one year (I’m 55 and had an otherwise healthy prostate). My Dr scheduled a retest a few month down the road. When that test came back a tad higher, that triggered a reference to a urologist who did a biopsy, a pretty easy procedure. The biopsy contained cancer cells – pretty easy diagnosis.
For treatment options, I sought out 2 surgeons, a local one and one at John Hopkins. There is a lot of data out there, and I believe I was given enough information to make an informed decision (I’m an engineer by training). The choice was mine, and I elected to use the DiVinci robot. The survival rates, as well as recovery rates for other treatments are a matter of record.
While at John Hopkins, I was asked to partake in a study already underway to determine a better marker than a PSA – I agreed.
As for the holistic treatment, I have taken a supplement that contains 50 mcg of selenium and 400 IU of Vit E for probably 30 years or more. I also take Ginko (120 mg x2daily, and had taken Saw Palmetto) I sauna frequently, but have been sedentary of late.
What do you think? Answer below!
Swiss drug maker Novartis reports flat second-quarter net profit of .7 billion
Filed under: Minneapolis Drug Treatment
He cited a positive opinion from European Union regulators for the use of Afinitor in the treatment of advanced breast cancer, which he said could push sales of the drug above the $ 1 billion mark. Gilenya, a recently launched oral therapy for multiple …
Read more on Minneapolis Star Tribune
More powerful, user-friendly heroin moving to the suburbs
Filed under: Minneapolis Drug Treatment
“It's to the point where it really alarms me that some people think it might be a recreational-type drug. Clearly it's not — it's the worst drug out there.” Chicago's suburbs aren't the only place heroin is popping up. “If you look at Minneapolis, if …
Read more on Chicago Sun-Times